Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525838 | 0.84 | GPR183 (0.54) | JAK2JAK1 | |
| SCHEMBL3529204 | 0.82 | SLC6A3 (0.44) | SLC6A3SLC6A4ALDH1A1MEN1KMT2A | |
| SCHEMBL8317366 | 0.81 | SLC6A3 (0.60) | SLC6A3SLC6A4ALDH1A1MEN1KMT2A | |
| SCHEMBL27621361 | 0.79 | SLC6A3 (0.40) | SLC6A3SLC6A4ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL5376820 | 0.78 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2AHPGDGAA | |
| SCHEMBL3530638 | 0.76 | SLC6A4 (0.43) | SLC6A3SLC6A4JAK2JAK1 | |
| SCHEMBL3528335 | 0.76 | SLC6A3 (0.43) | SLC6A3SLC6A4JAK2JAK1 | |
| SCHEMBL3523983 | 0.73 | CRHBP (0.41) | ALDH1A1MEN1KMT2AHPGDGAA | |
| SCHEMBL3526611 | 0.73 | ALDH1A1 (0.48) | ALDH1A1KMT2A | |
| SCHEMBL6153606 | 0.72 | CNR2 (0.40) | ALDH1A1GAAJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | SLC6A3 1496/4885SLC6A4 1478/4885ALDH1A1 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.